518 related articles for article (PubMed ID: 27568454)
41. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study.
Kristensen KE; Torp-Pedersen C; Gislason GH; Egfjord M; Rasmussen HB; Hansen PR
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):733-40. PubMed ID: 25633315
[TBL] [Abstract][Full Text] [Related]
42. Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand.
Teng TK; Tay WT; Ouwerkerk W; Tromp J; Richards AM; Gamble G; Greene SJ; Yiu KH; Poppe K; Ling LH; Lund M; Sim D; Devlin G; Loh SY; Troughton R; Ren QW; Jaufeerally F; Lee SGS; Tan RS; Soon DKN; Leong G; Ong HY; Yeo DPS; Lam CSP; Doughty RN
ESC Heart Fail; 2023 Apr; 10(2):1280-1293. PubMed ID: 36722315
[TBL] [Abstract][Full Text] [Related]
43. Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.
Allen LaPointe NM; Zhou Y; Stafford JA; Hernandez AF; Kramer JM; Anstrom KJ
Am J Cardiol; 2009 Jun; 103(11):1518-24. PubMed ID: 19463509
[TBL] [Abstract][Full Text] [Related]
44. Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis.
Alba MA; García-Martínez A; Prieto-González S; Espígol-Frigolé G; Butjosa M; Tavera-Bahillo I; Rodríguez-Pintó I; Hernández-Rodríguez J; Cid MC
Semin Arthritis Rheum; 2014 Jun; 43(6):772-7. PubMed ID: 24315461
[TBL] [Abstract][Full Text] [Related]
45. Angiotensin receptor blockers for heart failure.
Heran BS; Musini VM; Bassett K; Taylor RS; Wright JM
Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003040. PubMed ID: 22513909
[TBL] [Abstract][Full Text] [Related]
46. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
Shih CJ; Chu H; Ou SM; Chen YT
Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
[TBL] [Abstract][Full Text] [Related]
47. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
Gilstrap LG; Fonarow GC; Desai AS; Liang L; Matsouaka R; DeVore AD; Smith EE; Heidenreich P; Hernandez AF; Yancy CW; Bhatt DL
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28189999
[TBL] [Abstract][Full Text] [Related]
48. Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers in Acute Coronary Syndrome and Preserved Ventricular Ejection Fraction.
Cespón-Fernández M; Raposeiras-Roubín S; Abu-Assi E; Pousa IM; Queija BC; Paz RJC; Erquicia PD; Rodríguez LMD; Rodríguez EL; Busto MC; Barbeira SF; Romo AÍ
Angiology; 2020 Nov; 71(10):886-893. PubMed ID: 32757765
[TBL] [Abstract][Full Text] [Related]
49. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study).
AlJaroudi WA; Refaat MM; Habib RH; Al-Shaar L; Singh M; Gutmann R; Bloom HL; Dudley SC; Ellinor PT; Saba SF; Shalaby AA; Weiss R; McNamara DM; Halder I; London B;
Am J Cardiol; 2015 Apr; 115(7):924-31. PubMed ID: 25682436
[TBL] [Abstract][Full Text] [Related]
50. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis.
Khan MS; Fonarow GC; Ahmed A; Greene SJ; Vaduganathan M; Khan H; Marti C; Gheorghiade M; Butler J
Circ Heart Fail; 2017 Aug; 10(8):. PubMed ID: 28790052
[TBL] [Abstract][Full Text] [Related]
51. Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction.
Lee JH; Bae MH; Yang DH; Park HS; Cho Y; Lee WK; Jeong MH; Kim YJ; Cho MC; Kim CJ; Chae SC;
Korean J Intern Med; 2016 Mar; 31(2):267-76. PubMed ID: 26701233
[TBL] [Abstract][Full Text] [Related]
52. Do outpatient statins and ACEIs/ARBs have synergistic effects in reducing the risk of pneumonia? A population-based case-control study.
Kang JH; Kao LT; Lin HC; Wang TJ; Yang TY
PLoS One; 2018; 13(6):e0199981. PubMed ID: 29953536
[TBL] [Abstract][Full Text] [Related]
53. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
Ho CM; Lee CH; Lee MC; Zhang JF; Wang JY; Hu RH; Lee PH
BMC Cancer; 2018 Apr; 18(1):401. PubMed ID: 29631561
[TBL] [Abstract][Full Text] [Related]
54. Prescription and dosage of RAAS inhibitors in patients with chronic heart failure in the FAR NHL registry.
Špinarová M; Špinar J; Pařenica J; Špinarová L; Málek F; Lábr K; Ludka O; Jarkovský J
Vnitr Lek; 2019; 65(1):13-14. PubMed ID: 30823832
[TBL] [Abstract][Full Text] [Related]
55. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care.
Bidulka P; Fu EL; Leyrat C; Kalogirou F; McAllister KSL; Kingdon EJ; Mansfield KE; Iwagami M; Smeeth L; Clase CM; Bhaskaran K; van Diepen M; Carrero JJ; Nitsch D; Tomlinson LA
BMC Med; 2020 Jul; 18(1):195. PubMed ID: 32723383
[TBL] [Abstract][Full Text] [Related]
56. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.
Shih CJ; Chen HT; Chao PW; Kuo SC; Li SY; Yang CY; Tarng DC; Ou SM; Chen YT
J Hypertens; 2016 Mar; 34(3):567-74; discussion 575. PubMed ID: 26703918
[TBL] [Abstract][Full Text] [Related]
57. Doses of renin-angiotensin system inhibitors but not beta-blockers predict outcome after ST-elevation myocardial infarction.
Liu PY; Chen CL; Yu MC; Ko YL; Hsu SY; Chou HH; Yeh KH; Duan DM; Chen MH; Lin JF
Acta Clin Belg; 2019 Oct; 74(5):334-341. PubMed ID: 30295167
[No Abstract] [Full Text] [Related]
58. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.
Soler MJ; Noordzij M; Abramowicz D; de Arriba G; Basile C; van Buren M; Covic A; Crespo M; Duivenvoorden R; Massy ZA; Ortiz A; Sanchez JE; Petridou E; Stevens K; White C; Vart P; Gansevoort RT;
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1061-1072. PubMed ID: 34088718
[TBL] [Abstract][Full Text] [Related]
59. Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
Ouwerkerk W; Teng TK; Tromp J; Tay WT; Cleland JG; van Veldhuisen DJ; Dickstein K; Ng LL; Lang CC; Anker SD; Zannad F; Hung CL; Sawhney JPS; Naik A; Shimizu W; Hagiwara N; Wander GS; Anand I; Richards AM; Voors AA; Lam CSP
Eur J Heart Fail; 2020 Aug; 22(8):1472-1482. PubMed ID: 32583922
[TBL] [Abstract][Full Text] [Related]
60. Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - A real-world population study in Taiwan.
Pai PY; Muo CH; Sung FC; Ho HC; Lee YT
Int J Cardiol; 2016 Jul; 215():114-9. PubMed ID: 27111172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
